🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Dr. Ross Firestone's (Memorial Sloan Kettering Cancer Center) presentation at #DAVAWhistler focused on sequencing strategies for bispecific and CAR-T in MM, grounded in evolving resistance mechanisms. How prior BCMA-targeted therapies may influence treatment response was discussed. #Myeloma #Oncology

Mesenchymal stromal cells are being explored for steroid-refractory GVHD. Dr. Saad Kenderian (Mayo Clinic) at #DAVAWhistler discussed their mechanisms, variable clinical outcomes, and highlighted the importance of standardization and biomarker-driven approaches. #GVHD #Oncology

A holistic care model to strengthen coping during AlloHCT: In his #DAVAWhistler talk, Dr. Mohamed Sorror (Fred Hutch Cancer Center) outlined an approach that integrates comorbidity management & supportive care, with data pointing to potential gains in QoL and short-term outcomes. #Oncology

Starting Now: Hemoglobinopathies, Histiocytosis Moderated by: Vinay Jain #DAVAWhistler

Malaria: more than just a fever! Dr. Philip Rosenthal from UC San Francisco dives into its sinister link with endemic Burkitt’s lymphoma, Africa’s most common pediatric cancer Good news? New vax, better drugs, >90% survival in kids! #DAVAWhistler #malaria #GlobalHealth

Gene therapy for SCD & Beta Thal: high hopes, high hurdles Dr. J. Mark Sloan shares insights from early adult commercial use: •Ideal = young, severe, no organ damage •Mobilization is tough (no GCSF!) #genetherapy #DAVAWhistler

Starting Now: Emerging Myeloma Therapy Moderated by: Dr. Kenneth Shain Moffitt Cancer Center #DAVAWhistler

Belantamab mafodotin is back in the game! Ajay Nooka, MD, MPH highlights its solo act in DREAMM-2: durable responses, manageable safety- except the eye stuff DREAMM-3 flopped solo, but combos in DREAMM-7/8 shine Q8W dosing = fewer corneal issues Future’s BRIGHT #Oncology #DAVAWhistler

Teclistamab not working? Add a CELMoD twist! Dr. Malin Hultcrantz MD PhD explores teclistamab+ mezigdomide combo to fight T-cell exhaustion & BCMA escape in RRMM Trial opens May 2025-Watch this space! #Myeloma #CELMoD #DAVAWhistler

Sonrotoclax in myeloma: not the early bird, but maybe the second mouse? Dr. Rahul Banerjee, MD, FACP from Fred Hutch Cancer Center shares early data on this BCL2 inhibitor, promising all-oral doublet w/ dex. Lessons from venetoclax: triplets > doublets, dose wisely, watch infections! #DAVAWhistler

"Actinium-225–DOTA–daratumumab shows promise in Dara-refractory MM", Dr. Scott Goldsmith from City of Hope. Theranostics could boost specificity, 8 patients treated so far. Pre-targeted imaging, repeat dosing, & better radionuclide supply may unlock future potential #DAVAWhistler

Starting Now: Cytokines Moderated by: Dr. David Miklos Stanford Medicine #DAVAWhistler

Dr. Renier Brentjens from Roswell Park presents on IL-36γ armored CAR T cells at #DAVAWhistler, showcasing their enhanced functionality against solid tumors. He emphasizes their versatility and potential as a therapeutic breakthrough.

At #DAVAWhistler, Dr. Jacob Appelbaum Fred Hutch Cancer Center discusses Decoy-Resistant Interleukin-18 (DR-18) for relapse or pre-emptive treatment of MRD after AlloHCT for AML or MDS. The DR. DREAM (NCT06492707) trial tests the safety, side effects, and best dose of DR-18.

The 2025 DAVA Whistler Summit on Hematologic Malignancies has come to a close. We extend our gratitude to all participants for their valuable insights, expertise, and engaging questions and answers. #DAVAWhistler

Thankd to DAVA Oncology Dr. Estela Rodriguez Xiuning Le MD PhD to made a great meeting tonigth, hope that as more people are educated about MARIPOSA study and side effect management more patients will have this option EGFR Resisters EGFR Positive Lung Cancer UK Memorial Cancer Institute Memorial Healthcare System FLASCO OLACANCER #lungcancer

Xiuning Le MD PhD MD Anderson Cancer Center breaksdown the more complicated landscape of sequencing regimens in #EGFR #lungcancer DAVA Oncology EGFR Resisters #lcsm

DAVA Oncology is back with the 4th Kona Summit on Thoracic Malignancies! 🌟 We're bringing together expert scientists & clinicians to explore the latest advancements in thoracic cancer therapy. Check out the website for our confirmed faculty: dava.link/HawaiiLUNG25 #DAVALung

⭐️What a tremendous honor to join luminaries Dr. Jorge Garcia Case Comp Cancer Ctr University Hospitals and Dr. Sandy Srinivas Stanford Cancer Institute on stage at DAVA Oncology regional colloquium. We loved the opportunity to talk to the general medical oncologists face to face in a unique, completely open

Virtual registration for the 4th DAVA Summit on Thoracic Malignancies is now open! ✨Register now and don't miss this incredible opportunity to learn, connect, and be inspired. dava.link/HawaiiLung25Vi… #DAVALung